Patients on glucocorticosteroid therapy are at increased risk of gastrointestinal perforation. The associated morbidity and mortality of perforations in this group is increased, compared with normal groups. This difference is due to the delay between onset of clinical symptoms and treatment. In the presence of steroids, gastrointestinal perforation is more difficult to diagnose clinically because signs and symptoms of perforation are masked by the anti-inflammatory effect of the steroids.